Capurso L, Kock M, Ferrario F, Del Sette F, Gramolini C, Castiglioni C L
J Int Med Res. 1987 May-Jun;15(3):134-47. doi: 10.1177/030006058701500303.
A multi-centre study with epomediol discoids (200 mg three times daily for 30 days) versus placebo was carried out in 519 patients either with symptoms attributable to hepatopathy and/or alterations in the hepatic function. Epomediol was given to 257 patients chosen at random and the remaining 262 were given placebo. In cases of hepatopathy in which there was no severe damage to the hepatic parenchyma the symptoms of the disease were reduced and the laboratory parameters were improved on treatment with epomediol, whereas the activity of the drug was low in patients with chronic hepatopathy. This confirms that the clinical use of epomediol is most useful in cases of hepatopathy in which the change in hepatic function is still reversible.
一项针对519例有肝病相关症状和/或肝功能改变的患者开展的多中心研究，比较了艾波二醇片（每日3次，每次200mg，共30天）与安慰剂的疗效。257例患者被随机分配接受艾波二醇治疗，其余262例患者接受安慰剂治疗。在肝实质未受到严重损害的肝病病例中，使用艾波二醇治疗可减轻疾病症状并改善实验室指标，而在慢性肝病患者中该药物的活性较低。这证实了艾波二醇在肝功能改变仍可逆转的肝病病例中的临床应用最为有效。
